Ziopharm Oncology and Intrexon Corporation have entered into an exclusive channel partnership to develop DNA-based therapeutics to treat various cancers.
Under the agreement, Ziopharm will use Intrexon’s UltraVector technology to develop and commercialise DNA-based therapeutics.
Ziopharm will use Intrexon’s advanced transgene engineering platform to facilitate the controlled and precise cellular production of anti-cancer effectors.
Ziopharm will have rights to Intrexon’s complete human in vivo effector platform within the field of oncology, which includes two lead clinical-stage product candidates.
One of the product candidates is already in advanced Phase I study, while the other will be subject of an investigational new drug filing in the first half of 2011.